Relation between macrophage inflammatory protein-1 and intercellular adhesion molecule-1 and computed tomography findings in critically-ill saudi covid-19 patients

Alsayed, Eman; Hamza, Aljohara Mohmoud; Ali, Warda Demerdash Khalifa; Hassanein, Nagwa; Albassa, Waddah; Barry, Mohammad; AlFaifi, Abdullah Mofareh Mousa; Altayyar, Khalid Abdullah Sulaiman; Aboabat, Nuha Abdulrahman M; Alshaiddi, Wafa Khaled Fahad; Sabbah, Howayda Mohammad Abu; Alamri, Ahmed Hameed; Albabtain, Sara Abdullah Hamad

doi:10.1016/j.jiph.2022.10.023

Cited by 3 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Prior studies have reported elevated levels of E-selectin in ICUadmitted COVID-19 patients compared to non-ICU admitted COVID-19 patients. 11,12,49 The elevation of E-selectin was observed in severe ill COVID-19 patients as compared to mild cases of COVID-19 infection, 50 and healthy controls. 8,11,49,51 Furthermore, non-survivor COVID-19 patients admitted to the ICU had higher E-selectin levels than survivor patients admitted to the ICU.…”

Section: Discussionmentioning

confidence: 93%

“…These contrasting findings may be due to variations in the techniques used to evaluate soluble endothelial markers, including E-selectin, time of sample collection, and the presence of other comorbidities. Nevertheless, several studies have proposed E-selectin as a predictive marker for ICU admission in COVID-19 patients and for assessing disease severity and mortality in ICU-admitted COVID-19 patients 11,12,51,53 and of thrombosis in hospitalized COVID-19 patients. 51…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10] The levels of these endothelial markers (E-selectin, ICAM-1, and VCAM-1) have been linked to the severity of COVID. 8,[11][12][13][14] Complete blood count (CBC) parameters and CBCcalculated parameters, such as the neutrophil-tolymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelet-to-neutrophil ratio (PNR), and mean platelet volume to platelet count ratio (MPR), are useful indicators for diagnosing and predicting the severity and prognosis of COVID-19. [15][16][17][18] Furthermore, elevated NLR, PLR, and MPR values were observed in COVID-19 patients who passed away (PA) in the intensive care unit (ICU) compared to COVID-19 patients who were discharged (DC) from the ICU.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Correlation of circulating endothelial markers in COVID-19 patients admitted to the intensive care unit with laboratory data

Hakami,

Dobie,

Mobarki

et al. 2023

Eur J Inflamm

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a global concern with high morbidity and mortality rates. The role of endothelial cells in the progress of COVID-19 is well established. Therefore, the current study aimed to measure the endothelial markers and their correlation with the hematological parameters in intensive care unit-admitted COVID-19 patients. This study involved 111 adult participants, including 55 ICU-admitted patients with COVID-19 and 56 healthy controls. Levels of E-selectin, ICAM-1, and VCAM-1 in the plasma of the study participants were measured and correlated with hematological parameters. The study demonstrates that COVID-19 patients admitted to the ICU have higher levels of E-selectin, ICAM-1, and VCAM-1 compared to healthy controls ( p < .05). These elevated levels can serve as reliable indicators of endothelial dysfunction and early markers for the detection and prediction of endothelial cell involvement in COVID-19 complications. The findings of this study suggest that increased levels of E-selectin, VCAM-1, and ICAM-1 in patients with COVID-19 are indicative of the participation of endothelial cells in the pathogenesis of COVID-19 complications. Consequently, these endothelial markers are proposed as potential early indicators for predicting the severity of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation of circulating endothelial markers in COVID-19 patients admitted to the intensive care unit with laboratory data

Hakami,

Dobie,

Mobarki

et al. 2023

Eur J Inflamm

View full text Add to dashboard Cite

show abstract

COVID-19 pathogenesis

Zaidi,

Singh,

A.A Rizvi

et al. 2024

Progress in Molecular Biology and Translational Science

View full text Add to dashboard Cite

Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice

Condor Capcha,

Kamiar,

Robleto

et al. 2023

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

COVID-19 pneumonia causes acute lung injury and acute respiratory distress syndrome (ALI/ARDS) characterized by early pulmonary endothelial and epithelial injuries with altered pulmonary diffusing capacity and obstructive or restrictive physiology. Growth hormone–releasing hormone receptor (GHRH-R) is expressed in the lung and heart. GHRH-R antagonist, MIA-602, has been reported to modulate immune responses to bleomycin lung injury and inflammation in granulomatous sarcoidosis. We hypothesized that MIA-602 would attenuate rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury in a BSL-2 mouse model. Male and female K18-h ACE2 tg mice were inoculated with SARS-CoV-2/USA-WA1/2020, BSL-2-compliant recombinant VSV-eGFP-SARS-CoV-2-Spike (rVSV-SARS-CoV-2), or PBS, and lung viral load, weight loss, histopathology, and gene expression were compared. K18-h ACE2 tg mice infected with rVSV-SARS-CoV-2 were treated daily with subcutaneous MIA-602 or vehicle and conscious, unrestrained plethysmography performed on days 0, 3, and 5 (n = 7 to 8). Five days after infection mice were killed, and blood and tissues collected for histopathology and protein/gene expression. Both native SARS-CoV-2 and rVSV-SARS-CoV-2 presented similar patterns of weight loss, infectivity (~60%), and histopathologic changes. Daily treatment with MIA-602 conferred weight recovery, reduced lung perivascular inflammation/pneumonia, and decreased lung/heart ICAM-1 expression compared to vehicle. MIA-602 rescued altered respiratory rate, increased expiratory parameters (Te, PEF, EEP), and normalized airflow parameters (Penh and Rpef) compared to vehicle, consistent with decreased airway inflammation. RNASeq followed by protein analysis revealed heightened levels of inflammation and end-stage necroptosis markers, including ZBP1 and pMLKL induced by rVSV-SARS-CoV-2, that were normalized by MIA-602 treatment, consistent with an anti-inflammatory and pro-survival mechanism of action in this preclinical model of COVID-19 pneumonia.

show abstract

Relation between macrophage inflammatory protein-1 and intercellular adhesion molecule-1 and computed tomography findings in critically-ill saudi covid-19 patients

Cited by 3 publications

References 41 publications

Correlation of circulating endothelial markers in COVID-19 patients admitted to the intensive care unit with laboratory data

Correlation of circulating endothelial markers in COVID-19 patients admitted to the intensive care unit with laboratory data

COVID-19 pathogenesis

Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice

Contact Info

Product

Resources

About